secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-06-29T10:05:21+00:00
Accession:  0001193125-26-286747
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase stockholders approve 3M share increase under equity plan and director elections
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2020 Equity Incentive Plan increasing authorized shares by 3,000,000.
- Certificate of incorporation amended to limit liability of certain officers as permitted by Delaware law.
- Arvind Kush (70.3M for) and Dennis Berman (64.1M for) elected as Class III directors to 2029 meeting.
- CohnReznick LLP ratified as independent auditor for fiscal 2026 with 106.9M votes for.
- Advisory vote on executive compensation passed; company will hold future say-on-pay votes annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526286747/0001193125-26-286747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526286747/d68912d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-286747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer